NAV

CD-16 NK-92 cells

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
CD-16 NK-92 cells
DrugBank Accession Number
DB17465
Background

Not Available

Type
Biotech
Groups
Investigational
Synonyms
  • haNK
  • High-affinity CD16-expressing natural killer cell therapy
  • NK-92 [CD16.158V, ER IL-2]
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
SDM8K6W2YL
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentCervical Cancer / Colorectal Cancer / Gastric Cancer / Hepatocellular Carcinoma / Melanoma / Merkel Cell Carcinoma / Microsatellite Instability / Mismatch Repair Deficient (dMMR) / Non-Small Cell Lung Cancer (NSCLC) / Renal Cell Carcinoma (RCC) / Small Cell Lung Cancer (SCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Urothelial Carcinoma1
2Active Not RecruitingTreatmentPancreatic Cancer1
2Not Yet RecruitingTreatmentHigh Grade Glioma: Glioblastoma (GBM)1
2Not Yet RecruitingTreatmentStage II Squamous Cell Carcinoma of the Head and Neck / Stage III Squamous Cell Carcinoma of the Head and Neck / Stage IV Squamous Cell Carcinoma of the Head and Neck1
2RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia (ALL) / Acute Lymphoblastic Leukemia in Remission / Acute Myeloid Leukemia With Myelodysplasia-Related Changes / Acute Myeloid Leukemia With Variant MLL Translocations / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Chemotherapy-Related Leukemia / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements / ISS Stage II Plasma Cell Myeloma / ISS Stage III Plasma Cell Myeloma / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts / Myelodysplastic Syndrome With Gene Mutation / Myeloproliferative/Myelodysplastic Neoplasm / Previously treated Myelodysplastic Syndromes (MDS) / Recurrent Acute Myeloid Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Hodgkin Lymphoma / Recurrent Non-Hodgkin Lymphoma / Refractory Acute Lymphoblastic Leukemia (ALL) / Refractory Adult Acute Lymphoblastic Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Therapy-Related Myelodysplastic Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at January 24, 2023 00:52 / Updated at January 24, 2023 02:21